The clinical PARP inhibitors exhibit different sensitivity across cancer cell lines when measured in large-scale screens, enabling the prediction of distinct genomic biomarkers of drug sensitivity (Supplementary Table 1)27. The gene discussed is PARP1; the disease is cancer.